Sotyktu/Deucra Abstract Titles at ACR2022 10-14Nov2022 | BMY Message Board Posts


Bristol-Myers Squibb Co.

  BMY website

BMY   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  10303 of 10539  at  9/21/2022 8:39:31 AM  by

Baltasar


 In response to msg 10302 by  grafzeppelin
view thread

Re: Sotyktu/Deucra Abstract Titles at ACR2022 10-14Nov2022

 I understand, but from what I hear you are confusing safety and convenience.  Otezla's problem (other than lowest efficacy in the industry) is tolerability, not safety.  To a person, every derm I've talked to says Otezla is about as safe as anything they have ever had.
 
On the other hand, we have a medication guide that sure looks like the one JAKS give out.  Included in it are:  serious infections, viral reactivations(herpes zoster), tuberculosis, Rhabdomyolysis, malignancies including lymphomas, liver enzyme elevations, lipid elevations, and concerns over live vaccinations.  Those are safety concerns, not tolerability concerns.  
 
We work better, have more convenient dosing and are more tolerable but the data do not show at all that we are safer.  Not where close.  


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 1  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
10304 Re: Sotyktu/Deucra Abstract Titles at ACR2022 10-14Nov2022 grafzeppelin 4 9/21/2022 11:01:52 AM




Financial Market Data provided by
.
Loading...